MODEL VERDICT
Opus Genetics, Inc. (IRD)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 1, 2026 | NEUTRAL | 0.40 | $5.14 | CURRENT | — |
| Apr 24, 2026 | NEUTRAL | 0.37 | $5.23 | CURRENT | — |
| Apr 17, 2026 | NEUTRAL | 0.25 | $5.75 | CURRENT | — |
| Apr 16, 2026 | NEUTRAL | 0.25 | $5.71 | CURRENT | — |
| Apr 10, 2026 | NEUTRAL | 0.20 | $5.36 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 6 industry peers | $5.99 | +16.5% | 4% | B | Data |
| Price / Sales 6 industry peers | $4.97 | -3.3% | 3% | B | Model Driven |
| Weighted Output Blended model output | $6.13 | +19.3% | 100% | 44 | UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
Based on our peer multiples analysis with 4 valuation metrics, the model estimates IRD's fair value at $6.13 vs the current price of $5.14, implying +19.3% upside potential. Model verdict: Undervalued. Confidence: 44/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $6.13 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $3.52 (P10) to $7.60 (P90), with a median of $5.54.
IRD's current P/E of -2.4x compares to the industry median of 31.6x (1 peers in the group). This represents a -107.6% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
6 analysts cover IRD with a consensus rating of Buy. The consensus price target is $7.67 (range: $7.00 — $9.00), implying +49.2% upside from the current price. Grade breakdown: Strong Buy (0), Buy (6), Hold (0), Sell (0), Strong Sell (0).
The model confidence score is 44/100, based on: data completeness (6), peer quality (25), historical depth (5), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for IRD.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.